Ovary
The following MCCRC cancer treatment clinical trials are currently active. You may click on the trial number to link to a detailed description on PDQ, the National Cancer Institute's Web site for clinical trials.
| TRIO_015 | A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-Like Growth Factor Type 1 Receptor (IGF-1R) as Second-Line Therapy in Patients with Recurrent Platinum-Sensitive Ovarian Cancer |
For more information, please discuss these trials with your physician, contact the Operations Office or contact an MCCRC treating location near you.